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Abstract
Background
The existing frameworks for the evaluation of genetic and genomic applications clearly
address the technical and clinical value of a test, but are less concerned with the way
genetic services are delivered and organized. We therefore aimed to develop a comprehen-
sive new framework that includes an assessment of service delivery.
Methods
A new framework was built on the evaluation dimensions identified through a systematic
review of the existing frameworks and a Delphi survey of Italian experts in public health
genomics.
Results
Our framework has four sections. The first two sections, respectively, guide the evidence
collection process for the genetic test (analytic validity; clinical validity; clinical utility; per-
sonal utility) and its delivery models (organizational aspects; economic evaluation; ethical,
legal and social implications; patient perspective). The third section guides the formulation
of the research priorities to be addressed in future research. Finally, the fourth section sug-
gests three criteria to summarize the collected evidence (net benefit, cost-effectiveness,
feasibility).
Conclusion
We have successfully developed an evaluation framework for the evaluation of genetic tests
that includes an assessment of service delivery. It also introduces some neglected evalua-
tion dimensions such as personal utility and patient perspective.
PLOS ONE | https://doi.org/10.1371/journal.pone.0219755 August 5, 2019 1 / 15
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Pitini E, D’Andrea E, De Vito C, Rosso A,
Unim B, Marzuillo C, et al. (2019) A proposal of a
new evaluation framework towards implementation
of genetic tests. PLoS ONE 14(8): e0219755.
https://doi.org/10.1371/journal.pone.0219755
Editor: Yvonne Bombard, University of Toronto,
CANADA
Received: November 13, 2018
Accepted: July 2, 2019
Published: August 5, 2019
Copyright: © 2019 Pitini et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: EP, ED, CDV, AR, BU, CM, PV report
grants from Italian Ministry of Health, project
“Definizione e promozione di programmi per il
sostegno all’attuazione del Piano d’Intesa del 13/3/
13 recante Linee di indirizzo su La Genomica in
Sanità Pubblica”: http://www.ccm-network.it/
progetto.jsp?id=node/1914&idP=740; European
Union Horizon 2020 research and innovation
programme MSCA-RISE-2014 (Marie Skłodowska-
Introduction
The expanding knowledge of the human genome and the consequently growing availability of
genetic and genomic applications in recent decades are expected to revolutionize medicine [1].
The most significant promise lies in precision medicine, where medical decisions are tailored
to an individual’s characteristics, including the patient’s genetic profile [2]. However, there is
still a wide gap between reality and expectations, partly due to the absence of a completely sat-
isfactory framework for distinguishing useful innovations from unwarranted interventions
[3].
The existing frameworks for the evaluation of genetic and genomic applications rely mainly
on the technical and clinical assessments described in the well-known ACCE (Analytic valid-
ity, Clinical validity, Clinical utility, Ethical, legal and social implications) model [3, 4]. Never-
theless, such frameworks lack a structured evaluation of the implementation issues and how
these relate to the context in which the test will be used; i.e. how genetic services should be (re-
)organized to implement and deliver the new test [3]. Now more than ever the precision medi-
cine model is under the spotlight, and it appears clear that an evaluation limited to technical
performance and clinical outcomes is no longer sufficient for effective “research translation”[5,
6]. This is particularly true for publicly funded healthcare systems, where equity and resource
constraints are a major concern.
In Italy, the approval of genetic and genomics applications for funding by the National
Healthcare System is largely unregulated. For this reason, the National Plan for Public Health
Genomics has proposed, as a key objective, the development of a more comprehensive evalua-
tion framework for genetic and genomic applications, which could support decision-makers
in coverage decisions [7]. Our work was conducted as part of a project financed by the Italian
Ministry of Health to implement this plan and aims to develop a comprehensive evaluation
framework that includes an assessment of service delivery.
Materials and methods
A new framework was developed by combining a systematic review and a Delphi survey. The
systematic review was performed to review the need for a new framework and to provide a
basis for its creation. It aimed to identify and compare the existing frameworks, with a particu-
lar focus on their evaluation dimensions (i.e. analytic and clinical validity, clinical utility, etc.).
The Delphi survey was designed to support the systematic review and aimed to identify addi-
tional frameworks and to further explore the importance of their dimensions.
Throughout the paper, a genetic/genomic test is defined as an analysis of human chromo-
somes, DNA, RNA, genes, and/or gene products (e.g. enzymes or other proteins) that is pri-
marily used to detect heritable or somatic mutations, genotypes, or phenotypes related to
disease and health [8].
Systematic review
The systematic review is described elsewhere [3]. In brief, we included any document that
described an original evaluation framework for genetic tests. We searched the bibliographic
databases PUBMED, SCOPUS, ISI Web of Knowledge, Google Scholar and Google for all
English language articles between January 1990 and April 2017. This search was supplemented
by exploring the websites of the main government agencies and research organizations
involved in the evaluation of genetic tests. We screened the retrieved records by title, abstract
and full text. From the included records, we extracted information about the evaluation frame-
works, their evaluation dimensions and other methodological aspects.
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Delphi survey
Expert panel. The online Delphi survey involved 55 members of the Italian Network of
Public Health Genomics (GENISAP) (Fig 1) [7]. The network includes clinicians, epidemiolo-
gists, biologists, counselors, and health care managers who work at different levels in the field
of human genetics and public health (Table 1). The study did not require ethical approval
because it used a non-sensitive and anonymous questionnaire administered to experts. Partici-
pants were informed about the study during a face-to-face meeting, followed by individual
phone calls. In particular, it was explained that answering and sending back the questionnaire
would constitute consent to participate in the study.
Round I. We developed a two-part survey that includes both open- and closed-ended
questions. The questionnaire is shown in S2 File. In the first part, we asked the experts to list
the evaluation frameworks they were aware of. In the second part, we asked them to rate, on a
five-point scale ranging from 1 (minimal importance) to 5 (utmost importance), the following
dimensions, identified from the preliminary results of the systematic review: overview of the
disease and the test under study; analytic validity; clinical validity; clinical utility; ethical, legal
and social implications (ELSI); delivery models; organizational aspects; economic evaluation.
Each dimension was provided with a definition in order to standardize the interpretation.
Where, for a particular dimension, at least 65% of panelists agreed, we considered that a con-
sensus had been reached. In addition to the rating, the experts had the option of providing
comments and extra dimensions. The survey was piloted on a convenience sample of six aca-
demicians known to the research team. To increase the response rate, we contacted the experts
Fig 1. Steps of the Delphi survey.
https://doi.org/10.1371/journal.pone.0219755.g001
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by phone before emailing the definitive survey. They had three weeks to answer, during which
time two remainders were e-mailed.
Round II. Since the threshold of 65% had already been exceeded in the first round for all
the proposed evaluation dimensions, we used round II to evaluate one new dimension pro-
posed by some experts in round I. Therefore, after communicating the results of round I to the
panelists, we asked them to assign a score from 1 to 5 to the new dimension, which had also
been provided with a definition. As in round I, they had three weeks to answer, were given the
chance to provide comments and add dimensions and were encouraged by phone and e-mail
remainders. At the end of the second round, having reached a satisfactory level of agreement
(i.e.�65%) among the experts, we terminated the consensus procedure and communicated
the results to participants.
Framework development
The framework was built on the evaluation dimensions identified through the systematic
review and the Delphi procedure and refined in frequent meetings in the presence of the mod-
erator (P.V.). The analysis of the strengths and weaknesses of the existing frameworks guided
the whole process. The final version of the framework was sent to the Delphi panelists, and
their feedback was collected via e-mail.
Results
Systematic review
The systematic search identified 29 frameworks published between 2000 and 2017, mainly in
the USA and Europe [3]. They are mostly based on the ACCE Framework (n = 13 models), or
on the HTA process (n = 6), or both (n = 2). The remaining refer to the Wilson and Jungner
screening criteria (n = 3) or to a mixture of different preexisting frameworks (n = 5). The
ACCE framework is therefore the most popular approach to the evaluation of genetic tests,
followed by the HTA process. The evaluation dimensions retrieved were: test and clinical con-
dition overview, analytic validity, clinical validity, clinical utility, ELSI, delivery models,
Table 1. Characteristics of GENISAP experts.
Experts (total = 55)
Age (years), average, range 52.6 31–77
Gender, n, % of total
Male 24 43.6
Female 31 56.4
Region, n, % of total
Northern Italy 20 36.4
Central Italy 30 54.5
Southern Italy and Islands 5 9.1
Degree, n, % of total
Medicine 34 61.8
Biology 20 36.4
Economics 1 1.8
Primary employment, n, % of total
University 32 58.2
Healthcare institution 18 32.7
Government institution 5 9.1
https://doi.org/10.1371/journal.pone.0219755.t001
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organizational aspects, economic evaluation and patient perspective (the last of these was not
retrieved in the preliminary results and therefore was not included in the Delphi survey). Due
to the spread of the ACCE model, the most frequently employed dimensions were analytic
validity, clinical validity, clinical utility and ELSI. An economic evaluation was always pro-
posed but rather superficially. The delivery models and organizational aspects were frequently
missing in the retrieved evaluation frameworks and any analysis of these aspects, mostly repre-
sented by the HTA-based evaluation frameworks, was usually not well structured. Finally, the
direct experience of patients has rarely been considered as an independent evaluation dimen-
sion. The most frequently used format was the key questions format; about half of all frame-
works gave suggestions on the process of evidence review; and only five frameworks provided
criteria for deciding on the use of the test based on the evidence collected. Since decision mak-
ers are the main audience for which the evaluation process is intended, the lack of attention to
context-related aspects of testing (delivery models, economic evaluation, organizational
aspects) and to the decision-making process are arguably the main limitations of the retrieved
frameworks [3]. Finally, even where these frameworks were mainly developed to address sin-
gle-gene testing, some, such as the NHS UKGTN Gene Dossier and the Clinical Utility Gene
Card [9, 10], have also proved effective for applications based on next-generation sequencing.
Delphi survey
Of the 55 experts invited to participate in round 1, 43 completed the questionnaire, a response
rate of 78%. Three frameworks for the evaluation of genetic tests, already included in our sys-
tematic review, were suggested by these experts [4, 11, 12], together with one non-genetic test-
specific framework, the EUnetHTA core model [13]. Each dimension was ranked by at least 42
participants. The consensus was very strong (Table 2): 82% of respondents scored all dimen-
sions 4 or 5. In line with the findings from the literature, the dimensions of the ACCE frame-
work were the most highly regarded: overview of the disease and the test under study, analytic
validity, clinical validity, clinical utility and ELSI were all scored 4–5 by at least 95% of respon-
dents, followed by economic evaluation, which 93% of respondents scored 4–5. On the other
hand, delivery models, organizational aspects and research priorities were scored 4–5 by less
than 90% of experts, respectively 89%, 88% and 82%. Relevant comments were raised about
some dimensions (Table 3). For instance, it was proposed that the potential multidimensional-
ity of clinical utility should be addressed by defining the core standards used in its evaluation.
Table 2. Delphi consensus procedure: Score assigned to the proposed evaluation dimensions.
Evaluation dimension Score a (% of respondents)
1 2 3 4 5 NR
Test and clinical condition overview 0 0 2 14 84 0
Analytic validity 0 0 2 0 98 0
Clinical validity 0 0 2 7 89 2
Clinical utility 0 0 2 5 91 2
ELSI 0 0 3 23 72 2
Economic evaluation 0 0 7 42 51 0
Delivery models 0 0 9 28 61 2
Organizational aspects 0 0 12 39 49 0
Patient perspective 6 3 24 34 33 0
a Score: 1 = of little importance; 5 = of great importance
Abbreviations: ELSI, Ethical, Legal and Social Implications; NR, No Response
https://doi.org/10.1371/journal.pone.0219755.t002
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The importance of considering the economic impact of different delivery options for the test
under assessment, and the need for transparency of economic evidence reporting, were both
underlined. Finally, a new dimension, the patient perspective, was suggested (anticipating the
final results of the systematic review). Of the 43 experts who participated in round 1, 33 com-
pleted round 2, a repeat response rate of 76%. The patient perspective was ranked by all partic-
ipants and was scored 4–5 by 67%.
In summary, the Delphi survey confirmed the importance of the ACCE dimensions in
assessing the technical and clinical value of a genetic test, as had already emerged from the sys-
tematic review. Nonetheless, the experts appeared to be inclined to include the context-related
aspects of testing in the evaluation process.
Framework
General structure. We created a framework that integrates the two most popular
approaches to the evaluation of genetic tests i.e. the ACCE model, which is well-suited to the
assessment of the technical and clinical value of genetic tests, and the HTA approach, which
analyzes in a more systematic manner the organizational and delivery aspects of genetic ser-
vices. As a reference tool for the HTA approach we adopted the EUnetHTA core model, well
recognized at a European level and supported by the results of the Delphi survey [13]. The
final version of the framework, as approved by the GENISAP experts, is fully described in the
handbook attached as S1 File. It consists of four sections (Table 4). The first two sections guide
the process of evidence collection for, respectively, the genetic test itself and its delivery mod-
els. Each section comprises an introduction (“Test and clinical condition overview” and “Deliv-
ery models overview”) followed by the actual evaluation dimensions. Four dimensions refer to
the “genetic test” (analytic validity; clinical validity; clinical utility; personal utility) and four to
its “delivery models” (organizational aspects; economic evaluation; ELSI; patient perspective).
For each dimension, suggestions on which sources of evidence to consult are provided. The
third section deals with evidence gaps unearthed during the collection of evidence. Finally, the
fourth section suggests three criteria to summarize the collected evidence into practical points
for decision.
Section I—The genetic test. Section I starts with an introduction aimed at defining the
clinical condition and the test under examination. The clinical condition should be character-
ized in terms of clinical presentation, pathophysiology, genetic background, and public health
impact. The genetic test should be generally described, reporting the identifiable genes and
variants; technically defined, with a focus on the analytic procedure; and clinically contextual-
ized in terms of purpose, target population and actual use. This introduction is the foundation
for the study of the related dimensions, i.e. analytic validity, clinical validity, clinical utility and
Table 3. Delphi consensus procedure: Most relevant comments on the proposed evaluation dimensions.
Evaluation
dimension
Most relevant comments from the respondents
Clinical utility There is no agreement on which outcomes should be measured under the umbrella of
clinical utility (i.e. should it include personal and social aspects, as well as clinical?). This
issue therefore needs clarification.
Economic evaluation The economic impact of different delivery options for the genetic test under assessment
should be considered. Moreover, to contextualize the results of the existing economic
analyses, methodological aspects should be taken into account.
Organizational
aspects
Considering and contextualizing organizational aspects is very important, especially for
publicly funded healthcare systems.
Delivery models Important but difficult to assess, especially in the case of common complex diseases
https://doi.org/10.1371/journal.pone.0219755.t003
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personal utility. Analytic validity assesses the accuracy with which a particular genetic charac-
teristic, such as DNA sequence variants, chromosomal deletions, or biochemical indicators, is
identified in a given laboratory test [14]. It is a function of many factors of which the most
commonly considered are analytic sensitivity and specificity, accuracy, precision, robustness
and laboratory quality control [4, 15, 16]. Clinical validity assesses the ability of the test to accu-
rately and reliably detect or predict a clinical condition [17]. It consists of two parts: the assess-
ment of scientific validity, which is the evidence for gene-disease association; and the
assessment of test performance in terms of sensitivity, specificity, positive and negative predic-
tive value, and influencing factors [18]. Clinical utility assesses the health impact of the test in
Table 4. The proposed evaluation framework.
I. GENETIC TEST TEST AND CLINICAL CONDITION OVERVIEW
CLINICAL CONDITION
Clinical presentation and pathophysiology
Genetic background
Public health impact
GENETIC TEST
General features
Technical features
Clinical context
ANALYTIC VALIDITY
ANALYTIC SENSITIVITY
ANALYTIC SPECIFICITY
ACCURACY
PRECISION
ROBUSTNESS
LABORATORY QUALITY CONTROL
CLINICAL VALIDITY
SCIENTIFIC VALIDITY
TEST PERFORMANCE
Clinical sensitivity and specificity
Positive and negative predictive value
Modifiers
CLINICAL UTILITY
AVAILABLE INTERVENTIONS
EFFICACY
EFFECTIVENESS
SAFETY
PERSONAL UTILITY
II. DELIVERY MODELS DELIVERY MODELS OVERVIEW
HEALTHCARE PROGRAMS
LEVEL OF CARE
PATIENT PATHWAY
ORGANIZATIONAL ASPECTS
EXPECTED DEMAND
RESOURCES MANAGEMENT
OTHER ORGANIZATIONAL REQUIREMENTS
Education of professionals, patients and citizens
Information dissemination to professionals, patients and citizens
Cooperation, communication and coordination
Quality assurance, monitoring and control
BARRIERS TO IMPLEMENTATION
ECONOMIC EVALUATION
ETHICAL, LEGAL AND SOCIAL IMPLICATIONS
PATIENT PERSPECTIVE
III. RESEARCH PRIORITIES EVIDENCE GAPS & RESEARCH PRIORITIES
IV. DECISION POINTS NET BENEFIT
COST-EFFECTIVENESS
FEASIBILITY
https://doi.org/10.1371/journal.pone.0219755.t004
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terms of risks and benefits; it considers the availability, efficacy, effectiveness and safety of the
interventions to be put in place, depending on the test results, compared to the current practice
[14, 19]. Finally, personal utility considers the full range of personal reasons for testing and the
personal effect of testing, both of which are subjective and non-health related (or indirectly
health related), e.g. improving the patient’s understanding of the disease, enabling reproduc-
tive and life planning, etc. [20, 21].
Section II—Delivery models. Section II starts with an introduction aimed at defining the
delivery models for the provision of the test under study. A delivery model is the broad context
in which genetic tests are offered to individuals and families with or at risk of genetic disorders
[22]. It should be explained by three elements: the healthcare program, i.e. the set of interven-
tions preceding, following and including the genetic test, for a specific target population and
with a specific health purpose [23, 24]; the level of care (e.g. primary or specialist care level) in
which the provision of the genetic healthcare program is integrated and coordinated [25]; and
the patient pathway, i.e. the patient flow through different professionals from the point of
access to the genetic test to the diagnosis and treatment of the genetic disorder [26]. The
description of the delivery model is essential for studying the related dimensions, i.e. organiza-
tional aspects, economic evaluation, ELSI and patient perspective. Analysis of organizational
aspects leads to an estimate of the expected demand for the genetic test under study and the
resources needed to implement the related healthcare program. It should also consider possi-
ble barriers to implementation and further requirements such as education and training of
staff; information dissemination to professionals, patients and citizens; access to care; coopera-
tion, communication and coordination between and within organizations; quality assurance,
monitoring and control systems [13]. The economic dimension assesses the quantity and qual-
ity of cost-effectiveness and cost-utility evidence for alternative genetic testing programs [27].
The ELSI dimension considers an ensemble of heterogeneous concepts, namely the moral
value that society confers on the proposed interventions, the specific related norms and the
impact on the patient’s and his or her family’s social life [16]. Some of the most common issues
to address are: autonomy; equity; discrimination; privacy; confidentiality; informed consent;
societal values; psychosocial impact; and reproductive issues [28, 29]. The patient perspective
dimension collects qualitative and quantitative evidence on the perspective of patients who, as
the direct beneficiaries of the genetic program in question, can contribute to an understanding
of its value (N.B. the term patient is used to define any user of a genetic service) [30].
Section III. Section III was designed to address the evidence gaps that will almost cer-
tainly be unearthed during the evaluation process. These gaps, other than in the quantity and
quality of the evidence, may also relate to evidence generalizability and relevance to the specific
context of evaluation. In this section it should be defined whether the amount of evidence for
each dimension is exhaustive, incomplete or missing (Table A in S1 File). In the last two cases,
the evidence gaps should be formulated as specific research questions, in order to steer future
research and inform decision makers about the real state of the art.
Section IV. Section IV suggests three criteria for summarizing the evidence collected and
supporting the decision-making process on the use of the test: the net benefit, cost-effective-
ness and feasibility of the testing program.
The net benefit of an intervention is the balance between its benefits and harms. To justify
an intervention, benefits should adequately exceed harms. The dimensions to be considered
when assessing the net benefit of a testing program are: analytic validity, clinical validity, clini-
cal utility, personal utility, ELSI, and patient perspective. Based on these dimensions, the net
benefit can be assigned to one of four classes (A–D), ranging in descending order from positive
to negative (Table B in S1 File).
Genetic tests: A new framework for evaluation
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The analysis of the cost-effectiveness of an intervention should help decision makers under-
stand whether they are satisfied that the additional healthcare resources, required to make the
test available to those who could benefit from it, should be spent on the intervention rather
than on something else [31]. Four classes (A-D) of cost-effectiveness can be defined, ranging
in descending order from highly cost-effective to not cost-effective (Table C in S1 File).
The feasibility of genetic testing programs is determined from the organizational analysis. It
can be defined as the probability of overcoming the identified barriers to implementation and
can be rated in three classes (I–III) in descending order from easy to impossible (Table D in S1
File).
When considering net benefit and cost-effectiveness, decision makers should be given the
opportunity to take into account the quality of the supporting evidence. Specifically, the quality
of the evidence should be assessed using validated instruments and a minus or plus sign (indi-
cating low or high quality, respectively) should be added to each rating class, as appropriate.
The approach suggested by Section IV is not mandatory and the three criteria should be
used at the discretion of decision makers.
Discussion
We have developed a new framework aimed at producing technology assessments on which
decision makers, i.e. the Ministry of Health with the support of the National Agency for
Regional Healthcare Services and the National Institute of Health in Italy, can base national
provision and coverage decisions regarding genetic and genomic technologies.
The framework is distinguished by a dual focus on both the technology and its delivery
models. This is consistent with the HTA evolution process theorized by Battista, according to
which HTA has evolved through three distinct phases: the “machine phase”, focusing on the
technical performance of health technologies; the “clinical outcomes phase”, focusing on out-
comes of technology use in clinical settings; and the “delivery modes phase”, focusing on how
health services are organized and delivered [5]. While the first two phases are already well rep-
resented in the ACCE framework, the third phase needs more consideration. We think that
our framework, which develops the delivery models phase, would bring the evaluation process
closer to the context of implementation of genetic technologies, and thus help decision makers
to secure an efficient and equitable allocation of health care resources and services.
The first section of the framework, mainly based on the ACCE model, guides the assess-
ment of the genetic test. In particular, by adopting the dimensions of the ACCE model, this
section addresses some aspects of genetic tests that are fundamental to an understanding of
their clinical suitability, such as analytic and clinical validity, which are not adequately
addressed by standard methods of technology assessment. Because analytic validity cannot be
defined by a universal set of criteria, applicable to all kinds of test, we suggest looking at the cri-
teria most often addressed in the current literature [4, 14, 15]. As recommended by Burke &
Zimmern, we assessed separately two distinct properties of clinical validity: the widely cited
clinical test and the less reported gene-disease association [17]. While in some cases clinical
utility includes individual, familial, and societal benefits [32], we defined the essential evalua-
tion standards for clinical utility in their narrowest sense, i.e. the improvement in health out-
comes due to the test and the subsequent clinical interventions. We agree with Grosse &
Khoury that clinical utility should be measured using objective metrics and that health out-
comes are the most critical factor in setting priorities for public health, especially in publicly
funded healthcare systems [18]. Nevertheless, we understand that subjective, familial or socie-
tal benefits cannot be ignored. That is why we introduced the dimension of personal utility in
this first section and the ELSI dimension in section two. However, the assessment of these two
Genetic tests: A new framework for evaluation
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dimensions presents at least two challenges: establishing their weight in the overall assessment
of a genetic test [19, 32]; and defining the most useful and relevant criteria for exploring them,
given the heterogeneity of genetic tests and socio-cultural backgrounds. The work of Khoeler
et al. might help with personal utility, as they made an empirical effort to delineate its relevant
elements such as self-knowledge, knowledge of the condition, coping, and life planning [20,
33]. Our framework asks for a report on the most important and common considerations of
personal utility, even if only in qualitative terms, as they could help decision makers under-
stand the whole picture. Taking the example of predictive testing for BRCA1/2 mutations, per-
sonal aspects to be considered might be the shift of cancer risk perception, the personal
meaning ascribed to the mutation status, and the experience of being a mutation-negative/pos-
itive individual, with regard to the role of family dynamics [34, 35]. For instance, two qualita-
tive studies point out that family dynamics might challenge both mutation-positive and
-negative women, giving rise to psychosocial needs that should be addressed by healthcare pro-
fessionals [34, 35].
The second section of the framework, mainly based on the HTA approach, focuses on the
delivery models. When collecting economic, organizational, ELSI and patient perspective evi-
dence, a consideration of delivery models could be very valuable for decision makers. For
example, BRCA1/2 genetic tests could be delivered in a population screening program, where
healthy women invited for mammography may be advised to take a BRCA1/2 test on the basis
of their family history. In this case, local healthcare units would need to coordinate active call
of patients, risk assessments, genetic counseling, preventive or treatment pathways, cascade
screening etc. A BRCA1/2 genetic test could also be delivered in a specialist care setting, such
as an oncology clinic, where women with breast cancer may be advised to take the test on the
basis of their personal and family history. In this case, active call to recruit the general popula-
tion is not needed, and counseling and other interventions will probably take place in a special-
ist context. These two different delivery models will definitely have different costs, benefits,
organizational issues, ethical concerns and impact on patient perspective. Thus, they will
prove more or less appealing for decision makers. This is why shifting the focus from the
genetic test to its delivery models is fundamental when considering implementation questions.
While some existing frameworks include economic or organizational considerations within
clinical utility (e.g. the ACCE framework), we believe that treating these dimensions indepen-
dently could provide clearer guidance to evaluators and a more useful represention of the evi-
dence collected to decision makers. Regarding economic implications, our framework asks
that not only are the results of the existing economic analyses reported, but also their method-
ological details (e.g. comparator, perspective, sensitivity analysis). In this way decision makers
can understand the quality of the analysis performed and its relevance to their own context
[13]. Contextualization also affects organizational analysis, as it cannot but follow the level at
which decisions are taken, e.g. regional, departmental, hospital. Moreover, the multiplicity of
objectives and assessment criteria makes this analysis less pre-determined and more compli-
cated than others [13]. ELSI analysis faces the same challenge already described for personal
utility. In this case, help may come from the work of the US Genetic Alliance and Institute of
Medicine, which delineated the major concerns that should be addressed, such as equity, dis-
crimination and confidentiality [28, 29]. Moreover, it is necessary to consider that ELSI are
often interrelated, both within the ELSI dimension and with other evaluation dimensions. A
recent paper identified the interrelationships among more than 80 ELSI, combining them into
five clusters: patient preferences and experiences (e.g. patient-physician relationship, social
stigma, consequences for family members, etc.); patient quality of life and function (e.g. effect
on daily, social activities and social function, etc.); patient burden/harm (e.g. side effects and
adverse events; risk of incorrect test results, etc.); fairness (e.g. universal access; confidentiality;
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discrimination, etc.); and organizational (e.g. informed consent; continuum of patient care;
privacy, etc.) [36]. Finally, despite the increasing emphasis on the need for more patient-cen-
tered evaluations, a set of criteria for assessing the patient perspective is also lacking [37]. Our
framework requires that evidence on the patient perspective be derived from both quantitative
and qualitative studies, e.g. surveys or interviews. This is the only way to learn about the expe-
riences, attitudes, beliefs and expectations of living with an illness and using a genetic service.
Section three addresses one of the major difficulties encountered in the evaluation of
genetic tests, i.e. the collection of evidence. Finding the answer to some of the evaluation ques-
tions, especially those related to the clinical value and to the implementation of a genetic test,
is not a simple matter. In fact, while gene discovery studies are carried out relatively rapidly,
translation studies (including randomized clinical trials and appropriately conducted observa-
tional studies) often lag behind [6, 38]. Moreover, the lack of evidence on effectiveness also
affects the evaluation of cost-effectiveness [39].
Section four of the framework aims to synthesize the collected evidence into practical points
for decision. We think that it is critical for decision makers to consider the net benefit, cost-
effectiveness and feasibility of a particular test, as well as the quality of scientific evidence sup-
porting it. Nevertheless, defining an appraisal framework is beyond the scope of our work. In
this regard, it should be made clear that our framework only covers the process of evidence
collection. This is undoubtedly the main focus of technology assessment, but it is only one step
of an ideal decision pathway. Evidence collection should be preceded by a priority setting
phase, as the number of available genetic tests far outweighs the resource available for their
assessment, and followed by an appraisal phase, which provides recommendations on the use
of a test by prioritising the various elements of the large body of evidence collected.
If the comprehensiveness of the evaluation dimensions is the strength of our framework, it
is also the main limitation. In fact, the considerable time needed to complete the evaluation
process clashes with the rapid development and dissemination of genetic tests. Moreover, the
lack of direct evidence for several dimensions would make it necessary to refer to grey litera-
ture, resulting in a higher probability of error and a reduced quality of evidence. Finally, deci-
sion makers might be hampered by the large amount of information collected (and therein lies
the utility of section four). Another limitation of our work might be the intention to use a sin-
gle framework to evaluate different types of test, but we do not claim the framework to be a
universal guide. It is a wayfinder that can be adapted to the individual test under study, for
which particular dimensions and criteria might be appropriate, optional or not applicable. We
chose a handbook format to ensure flexibility, it being less restrictive than a questionnaire or
checklist. On the other hand, we believe that the adoption of a single framework for the evalua-
tion of different types of test might allow comparison of technologies and the sharing of infor-
mation. Moreover, our framework could be of benefit for the assessment of other types of
technologies and services. In fact, by bringing together the ACCE model with the HTA
approach, we have created a framework that adopts genetic test-specific and widely recognized
dimensions and terminology, but is conceptually and structurally similar to generic technology
assessments. Finally, two main concerns result from the selected Delphi survey sample, i.e. the
GENISAP experts. The first one is the representativeness of the sample. In fact, while the pri-
mary audience of our framework is represented by Italian national and local government deci-
sion makers, the GENISAP sample comprises predominantly academics. Nevertheless, in Italy
academics are often consulted for healthcare decision making, and are particularly involved in
the evidence collection for decision making. For this reason, we think that the contribution of
the GENISAP experts was extremely useful for the development of the framework, given also
their specific experience in the field of public health genomics. The second concern is the gen-
eralizability of our framework to other countries. In fact, it was developed with the
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contribution of Italian experts only. Nevertheless, it is also based on information derived from
a systematic international literature review, so we believe it may be a suitable model for other
health systems.
Even though the final version of the framework was approved by the GENISAP experts, to
gain first-hand experience we are currently validating it by assessing the BRCA1/2 genetic test
for susceptibility to breast and ovarian cancer. The framework seems to be an efficient tool for
collecting and organizing existing evidence, although it takes some time to complete. More-
over, as anticipated in our previous work [23], the usefulness of considering both the genetic
test and its delivery model is confirmed. Nevertheless, we are aware that our framework must
be considered “under development” until it has been definitively validated.
Our work was financed by the Italian Ministry of Health to implement the 2013 National
Plan for Public Health Genomics, one of the few examples of a national policy in Europe
aimed at translating genomics into clinical practice at a central level [40]. A further step has
recently been made with the approval of the National Plan for Innovation of the Health System
based on omics sciences [41]. It outlines the ways in which innovations in the omics field
should benefit the National Health System in the areas of prevention, diagnosis and care, tak-
ing into account effectiveness and sustainability [41].
In conclusion, our framework aims to broaden the evaluation of genetic and genomic tests
to include service delivery. While the context dependence of this analysis reduces its transfer-
ability, it is the only way to meet the specific requirements of decision makers. Italian experts
gave positive feedback, but the framework will probably require further refinement. Subse-
quently, regular updates will be needed to keep pace with new innovations in the field.
Supporting information
S1 File. Evaluation framework handbook.
(PDF)
S2 File. Delphi survey questionnaire.
(PDF)
S3 File. Delphi survey dataset.
(XLS)
Acknowledgments
We would like to thank the GENISAP experts for their participation in the Delphi survey.
Author Contributions
Conceptualization: Erica Pitini, Elvira D’Andrea, Antonio Federici, Emilio Di Maria, Paolo
Villari.
Data curation: Erica Pitini.
Formal analysis: Erica Pitini, Elvira D’Andrea, Annalisa Rosso, Brigid Unim.
Funding acquisition: Carolina Marzuillo, Antonio Federici, Paolo Villari.
Investigation: Erica Pitini.
Methodology: Erica Pitini, Elvira D’Andrea, Corrado De Vito, Brigid Unim, Emilio Di Maria.
Project administration: Erica Pitini, Corrado De Vito, Carolina Marzuillo, Antonio Federici,
Paolo Villari.
Genetic tests: A new framework for evaluation
PLOS ONE | https://doi.org/10.1371/journal.pone.0219755 August 5, 2019 12 / 15
Supervision: Corrado De Vito, Antonio Federici, Emilio Di Maria, Paolo Villari.
Validation: Erica Pitini, Elvira D’Andrea, Annalisa Rosso, Paolo Villari.
Writing – original draft: Erica Pitini.
Writing – review & editing: Erica Pitini, Elvira D’Andrea, Corrado De Vito, Annalisa Rosso,
Brigid Unim, Carolina Marzuillo, Antonio Federici, Emilio Di Maria, Paolo Villari.
References
1. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 2001;
285(5):540–4. https://doi.org/10.1001/jama.285.5.540 PMID: 11176855
2. Ricciardi W, Boccia S. Assessment of genomics as a priority for public health. Eurohealth (Lond). 2007;
13(4):4–6.
3. Pitini E, De Vito C, Marzuillo C, D’Andrea E, Rosso A, Federici A, et al. How is genetic testing evalu-
ated? A systematic review of the literature. Eur J Hum Genet. 2018; 26(5):605–15. https://doi.org/10.
1038/s41431-018-0095-5 PMID: 29422659
4. Haddow J, Palomaki G. ACCE: A Model Process for Evaluating Data on Emerging Genetic Tests. In:
Khoury M, Little J, Burke W, editors. Human Genome Epidemiology: A Scientific Foundation for Using
Genetic Information to Improve Health and Prevent Disease. Oxford: Oxford University Press; 2004.
Pp. 217–33.
5. Battista RN. Expanding the scientific basis of health technology assessment: a research agenda for the
next decade. Int J Technol Assess Health Care. 2006; 22(3):275–80. PMID: 16984053
6. Khoury MJ. No Shortcuts on the Long Road to Evidence-Based Genomic Medicine. JAMA. 2017; 318
(1):27. https://doi.org/10.1001/jama.2017.6315 PMID: 28570728
7. Simone B, Mazzucco W, Gualano MR, Agodi A, Coviello D, Bricarelli D, et al. The policy of public health
genomics in Italy. Health Policy (New York). 2013; 110(2–3):214–9.
8. Ferreira-Gonzalez A, Teutsch S, Williams MS, Au SM, Fitzgerald KT, Miller PS, et al. US system of
oversight for genetic testing: a report from the Secretary’s Advisory Committee on Genetics, Health and
Society. Per Med. 2008; 5(5):521–8. https://doi.org/10.2217/17410541.5.5.521 PMID: 20490368
9. UK Genetic testing Network. Promoting gene testing together. Fifth report of the UK Genetic Testing
Network. 2017. Available from https://ukgtn.nhs.uk/fileadmin/uploads/ukgtn/Documents/Resources/
Library/Reports_Guidelines/UKGTN_Biennial_report_2017.pdf. Cited 6 June 2018.
10. Arslan-Kirchner M, Arbustini E, Boileau C, Charron P, Child AH, Collod-Beroud G, et al. Clinical utility
gene card for: Hereditary thoracic aortic aneurysm and dissection including next-generation sequenc-
ing-based approaches. Eur J Hum Genet. 2016 J; 24(1):146–50.
11. Schmidtke J, Cassiman J-J. The EuroGentest clinical utility gene cards. Eur J Hum Genet. Nature.
2010; 18(9):1068. https://doi.org/10.1038/ejhg.2010.85 PMID: 20725082
12. Kroese M, Zimmern RL, Farndon P, Stewart F, Whittaker J. How can genetic tests be evaluated for clini-
cal use? Experience of the UK Genetic Testing Network. Eur J Hum Genet. 2007; 15(9):917–21. https://
doi.org/10.1038/sj.ejhg.5201867 PMID: 17534375
13. EUnetHTA Joint Action 2 WP 8. HTA Core Model version 3.0. 2013.Available from: http://eunethta.eu/
sites/5026.fedimbo.belgium.be/files/HTACoreModel3.0.pdf Cited 30 August 2017.
14. Burke W. Genetic tests: clinical validity and clinical utility. Curr Protoc Hum Genet. 2014; 81:9.15.1–8.
15. Sun F, Bruening W, Erinoff E, Schoelles KM. Addressing Challenges in Genetic Test Evaluation: Evalu-
ation Frameworks and Assessment of Analytic Validity. Rockville: Agency for Healthcare Research
and Quality (US); 2011.
16. Becker F, van El CG, Ibarreta D, Zika E, Hogarth S, Borry P, et al. Genetic testing and common disor-
ders in a public health framework: how to assess relevance and possibilities. Eur J Hum Genet. 2011;19
Suppl 1:S6-44.
17. Zimmern RL, Kroese M. The evaluation of genetic tests. J Public Health (Bangkok). 2007; 29(3):246–
50.
18. Burke W, Zimmern R. Moving beyond acce: An Expanded Framework for Genetic Test Evaluation.
2007. Available from: http://www.phgfoundation.org/documents/369_1409657043.pdf. Cited 6 June
2018.
19. Grosse SD, Khoury MJ. What is the clinical utility of genetic testing? Genet Med. 2006; 8(7):448–50.
PMID: 16845278
Genetic tests: A new framework for evaluation
PLOS ONE | https://doi.org/10.1371/journal.pone.0219755 August 5, 2019 13 / 15
20. Bunnik EM, Janssens ACJW, Schermer MHN. Personal utility in genomic testing: is there such a thing?
J Med Ethics. 2015; 41(4):322–6. https://doi.org/10.1136/medethics-2013-101887 PMID: 24872596
21. Kohler JN, Turbitt E, Biesecker BB. Personal utility in genomic testing: a systematic literature review.
Eur J Hum Genet. 2017; 25(6):662–8. https://doi.org/10.1038/ejhg.2017.10 PMID: 28295040
22. Unim B, Lagerberg T, Pitini E, De Vito C, Vacchio MR, Adamo G, et al. Identification of Delivery Models
for the Provision of Predictive Genetic Testing in Europe: Protocol for a Multicentre Qualitative Study
and a Systematic Review of the Literature. Front Public Heal. 2017; 5:223.
23. D’Andrea E, Marzuillo C, De Vito C, Di Marco M, Pitini E, Vacchio MR, et al. Which BRCA genetic test-
ing programs are ready for implementation in health care? A systematic review of economic evalua-
tions. Genet Med. 2016; 18(12):1171–80. https://doi.org/10.1038/gim.2016.29 PMID: 27906166
24. Di Marco M, D’Andrea E, Panic N, Baccolini V, Migliara G, Marzuillo C, et al. Which Lynch syndrome
screening programs could be implemented in the “real world”? A systematic review of economic evalua-
tions. Genet Med. 2018; https://doi.org/10.1038/gim.2017.244 PMID: 29300371
25. Battista RN, Blancquaert I, Laberge A, van Schendel N, Leduc N. Genetics in Health Care: An Overview
of Current and Emerging Models. Public Health Genomics. 2012; 15(1):34–45. https://doi.org/10.1159/
000328846 PMID: 21734357
26. Gu Y, Warren JR, Day KJ. Unleashing the power of human genetic variation knowledge: New Zealand
stakeholder perspectives. Genet Med. 2011; 13(1):26–38. https://doi.org/10.1097/GIM.
0b013e3181f9648a PMID: 21068671
27. Hornberger J, Doberne J, Chien R. Laboratory-Developed Test—SynFRAME: An Approach for Assess-
ing Laboratory-Developed Tests Synthesized from Prior Appraisal Frameworks. Genet Test Mol Bio-
markers. 2012; 16(6):605–14. https://doi.org/10.1089/gtmb.2011.0177 PMID: 22300513
28. The New York-Mid-Atlantic Consortium for Genetic and Newborn Screening Services. Ethical, Legal,
and Social Issues. Understanding Genetics: A New England Guide For Patients and Health Profession-
als. Washington: Genetic Alliance; 2010.
29. Social, Legal, and Ethical Implications of Genetic Testing. In: Andrews L, Fullarton J, Holtzman N, edi-
tors. Assessing Genetic Risks: Implications for Health and Social Policy. Washington: National Acade-
mies Press; 1994. p. 247–54.
30. D’Andrea E, Lagerberg T, De Vito C, Pitini E, Marzuillo C, Massimi A, et al. Patient experience and utility
of genetic information. A cross-sectional study among patients tested for cancer susceptibility and
thrombophilia. Eur J Hum Genet. 2018; 26(4):518–26. https://doi.org/10.1038/s41431-017-0083-1
PMID: 29374276
31. Drummond M, Sculpher M, Claxton K, Torrance G, Stoddart G. Methods for the economic evaluation of
health care programmes. 4th ed. Oxford: Oxford University Press; 2015.
32. Dotson WD, Bowen MS, Kolor K, Khoury MJ. Clinical utility of genetic and genomic services: context
matters. Genet Med. 2016; 18(7):672–4. https://doi.org/10.1038/gim.2015.153 PMID: 26656648
33. Kohler JN, Turbitt E, Lewis KL, Wilfond BS, Jamal L, Peay HL, et al. Defining personal utility in geno-
mics: A Delphi study. Clin Genet. 2017; 92(3):290–7. https://doi.org/10.1111/cge.12998 PMID:
28218387
34. Bakos AD, Hutson SP, Loud JT, Peters JA, Giusti RM, Greene MH. BRCA mutation-negative women
from hereditary breast and ovarian cancer families: a qualitative study of the BRCA -negative experi-
ence. Heal Expect. 2008; 11(3):220–31.
35. Hoskins LM, Werner-Lin A. A Multi-Case Report of the Pathways To and Through Genetic Testing and
Cancer Risk Management for BRCA Mutation-Positive Women Aged 18–25. J Genet Couns. 2013; 22
(1):27–38. https://doi.org/10.1007/s10897-012-9521-y PMID: 22864682
36. Krahn MD. Picturing ELSI+ (Ethical, Legal, and Social Issues Plus Patient Values and Preferences) in
Health Technology Assessment. 2019 April 16 [cited 13 May 2019]. In: Symposium CADTH [Internet].
Alberta, Canada: 2019. Available from https://symposium.cadth.ca/equity-ethics-and-social-values/
37. Gagnon M, Desmartis M, Lepage-Savary D, Gagnon J, St-Pierre M, Rhainds M, et al. Introducing
patients’ and the public’s perspectives to health technology assessment: A systematic review of interna-
tional experiences. Int J Technol Assess Health Care. 2011; 27(01):31–42.
38. Khoury MJ, Berg A, Coates R, Evans J, Teutsch SM, Bradley LA. The Evidence Dilemma In Genomic
Medicine. Health Aff. 2008; 27(6):1600–11.
39. Marzuillo C, De Vito C, D’Andrea E, Rosso A, Villari P. Predictive genetic testing for complex diseases:
a public health perspective. QJM. 2014; 107(2):93–7. https://doi.org/10.1093/qjmed/hct190 PMID:
24049051
40. Mazzucco W, Pastorino R, Lagerberg T, Colotto M, D’Andrea E, Marotta C, et al. Current state of geno-
mic policies in healthcare among EU member states: results of a survey of chief medical officers. Eur J
Public Health. 2016; 27(5):155.
Genetic tests: A new framework for evaluation
PLOS ONE | https://doi.org/10.1371/journal.pone.0219755 August 5, 2019 14 / 15
41. Boccia S, Federici A, Siliquini R, CalabròGE, Ricciardi W. Implementation of genomic policies in Italy:
the new National Plan for innovation of the Health System based on omics sciences. Epidemiol Biostat
Public Heal. 2017; 14(4).
Genetic tests: A new framework for evaluation
PLOS ONE | https://doi.org/10.1371/journal.pone.0219755 August 5, 2019 15 / 15
